natgillin/translations-raw huggingface dataset:
However due to a higher risk of yellow fever vaccine-associated severe and potentially fatal disease in persons from 60 years of age, the vaccine should only be given when it is considered that there is a considerable and unavoidable risk of acquiring yellow fever infection (see sections 4.4 and 4.8).
Ker je pri osebah nad 60 let starosti višje tveganje za pojav hudih in potencialno usodnih bolezni, ki so povezane s cepivom proti rumeni mrzlici, je treba cepljenje opraviti samo v primeru velikega in neizogibnega tveganja za okužbo z rumeno mrzlico (glejte poglavji 4. 4 in 4. 8).
Re-vaccination with one dose of 0.5 ml is recommended every 10 years in persons considered to be at risk of exposure.
Revakcinacija Revakcinacija z enim odmerkom 0, 5 ml se priporoča vsakih 10 let pri osebah s tveganjem za izpostavljenost.
International Health Regulations require re-vaccination, using the same dose as for primary vaccination, at intervals of 10 years in order to retain a valid certificate.
Mednarodna zdravstvena pravila za ohranitev veljavnosti potrdila zahtevajo ponovno cepljenje v časovnih presledkih po 10 let z uporabo enakega odmerka kot ob primarnem cepljenju.
It is preferable that the vaccine is injected by the subcutaneous route
Priporočljivo je injicirati cepivo po možnosti v podkožje.
Intramuscular injection may be performed if this is in accordance with applicable official recommendations.
Lahko se opravi intramuskularna injekcija, če je to v skladu z veljavnimi uradnimi priporočili.
For intramuscular use the recommended injection sites are the anterolateral aspect of the thigh in the infants and toddlers (6 months up to 2 years of age) and the deltoid muscle in older children and adults.
Priporočljivi mesti za intramuskularno injekcijo sta anterolateralna stran stegna pri dojenčkih in malčkih (od 6 mesecev do 2 let starosti) ter deltoidna mišica pri starejših otrocih in odraslih.
DO NOT INJECT INTRAVASCULARLY
NE SME SE INJICIRATI V ŽILO
See section 6.6. for instructions on reconstitution
Glejte poglavje 6. 6. za navodila o rekonstituciji.
Hypersensitivity reaction to eggs, chicken proteins or to any component of STAMARIL Serious hypersensitivity reactions (e.g., anaphylaxis) after a previous dose of any yellow fever vaccine.
Huda preobčutljivostna reakcija (npr. anafilaksa) po predhodnem odmerku kateregakoli cepiva proti rumeni mrzlici.
Immunosuppression, whether congenital, idiopathic or as a result of treatment with systemic steroids (greater than the standard dose of topical or inhaled steroids), radiotherapy or cytotoxic drugs.
Imunosupresija, bodisi prirojena, idiopatska ali kot posledica zdravljenja s sistemskimi steroidi (večji odmerki topičnih ali inhalacijskih steroidov kot običajno), radioterapija ali citotoksična zdravila.
History of thymus dysfunction (including thymoma, thymectomy) Symptomatic HIV infection Asymptomatic HIV infection when accompanied by evidence of impaired immune function (see section 4.4).
Asimptomatska okužba s HIV, kadar so prisotni dokazi o okrnjenem imunskem delovanju (glejte poglavje 4. 4).
Age less than 6 months (see sections 4.2 and 4.4).
Starost manj kot 6 mesecev (glejte poglavji 4. 2 in 4. 4).
Current severe febrile illness.
Trenutna huda vročinska bolezen.
4.4 Special warnings and precautions for use
4. 4 Posebna opozorila in previdnostni ukrepi pri uporabi
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of anaphylaxis or other severe hypersensitivity reaction following administration of the vaccine.
Kot pri vseh cepivih za injiciranje mora biti vedno na razpolago ustrezno medicinsko zdravljenje in nadzor za primer anafilakse ali kakšne druge hude preobčutljivostne reakcije po uporabi cepiva.
Before
STAMARIL je treba uporabiti samo pri tistih osebah, ki imajo / bodo imele visoko tveganje za okužbo z virusom rumene mrzlice ali morajo biti cepljene zaradi izpolnjevanja Mednarodnih zdravstvenih pravil.
15 considering administration of yellow fever vaccine, care should be taken to identify those who might be at increased risk of adverse reactions following vaccination (see section 4.3 and below).
Pred odločitvijo za cepljenje s cepivom proti rumeni mrzlici je treba poskrbeti za prepoznavo oseb z visokim tveganjem za neželene reakcije po cepljenju (glejte poglavje 4. 3 in spodaj).
Yellow fever vaccine associated neurotropic disease Very rarely, yellow fever vaccine-associated neurotropic disease (YEL-AND) has been reported following vaccination, with sequelae or with fatal outcome in some cases (see section 4.8).
16 Nevrotropna bolezen, povezana s cepivom proti rumeni mrzlici Obstajajo zelo redka poročila o nevrotropni bolezni, povezani s cepivom proti rumeni mrzlici (YEL - AND), ki se pojavi po cepljenju, v nekaterih primerih s posledicami ali s smrtnim izidom (glejte poglavje 4. 8).
Clinical features have appeared within one month of vaccination and include high fever with headache that may progress to include one or more of the following: confusion, encephalitis/encephalopathy, meningitis, focal neurological deficits, or Guillain Barré syndrome.
Klinični znaki se pojavijo v enem mesecu po cepljenju in vključujejo visoko vročino z glavobolom, ki lahko napreduje in obsega enega ali več od naslednjih znakov: zmedenost, encefalitis/ encefalopatija, meningitis, žariščni nevrološki izpadi ali sindrom Guillain- Barré.
To date, those affected have been primary vaccinees.
Doslej so bile prizadete le osebe po primarnem cepljenju.
The risk appears to be higher in those aged over 60 years, although cases have been also reported in younger persons.
Zdi se, da je tveganje večje pri osebah nad 60 let starosti, čeprav poročajo tudi o primerih pri mlajših osebah.
Yellow fever vaccine-associated viscerotropic disease Very rarely, yellow fever vaccine-associated viscerotropic disease (YEL-AVD) resembling fulminant infection by wild-type virus has been reported following vaccination (see section 4.8).
Viscerotropna bolezen, povezana s cepivom proti rumeni mrzlici Obstajajo zelo redka poročila o viscerotropni bolezni, povezani s cepivom proti rumeni mrzlici (YEL - AVD), ki se pojavi po cepljenju in je podobna fulminantni okužbi z divjim tipom virusa (glejte poglavje 4. 8).
The clinical presentation may include fever, fatigue, myalgia, headache, hypotension, progressing to one or more of metabolic acidosis, muscle and liver cytolysis, lymphocytopenia and thrombocytopenia, renal failure and respiratory failure.
Klinična slika lahko vključuje vročino, utrujenost, bolečine v mišicah, glavobol, hipotenzijo, in napreduje v eno ali več od naslednjih stanj: metabolna acidoza, mišična in jetrna citoliza, limfocitopenija in trombocitopenija, ledvična odpoved in dihalna odpoved.
The mortality rate has been around 60%.
Stopnja umrljivosti znaša okoli 60%.
To date, all cases of YEL- AVD have been in primary vaccinees with onset within 10 days of vaccination.
Doslej so bile v vseh primerih YEL- AVD prizadete le osebe po primarnem cepljenju z začetkom v prvih 10 dneh po cepljenju.
The risk appears to be higher in those aged over 60 years although cases have also been reported in younger persons.
Zdi se, da je tveganje večje pri osebah nad 60 let starosti, čeprav poročajo tudi o primerih pri mlajših osebah.
Disease of the thymus gland has also been recognised as a potential risk factor (see section 4.3 and section 4.8).
Tudi bolezen timusa naj bi predstavljala enega od potencialnih dejavnikov tveganja (glejte poglavje 4. 3 in poglavje 4. 8).
Immunosuppressed persons STAMARIL must not be administered to immunosuppressed persons (see section 4.3).
Imunosuprimirane osebe Cepiva STAMARIL se ne sme uporabljati pri imunosuprimiranih osebah (glejte poglavje 4. 3).
If the immunosuppression is temporary, vaccination should be delayed until the immune function has recovered.
Če je imunosupresija prehodna, je treba cepljenje odložiti, dokler se imunsko delovanje ponovno ne okrepi.
In patients who have received systemic corticosteroids for 14 days or more, it is advisable to delay vaccination until at least one month after completing the course.
Pri bolnikih, ki prejemajo sistemske kortikosteroide 14 dni ali več, je priporočljivo odložiti cepljenje na vsaj en mesec po zaključku zdravljenja.
HIV infection STAMARIL must not be administrated to persons with symptomatic HIV infection or with asymptomatic HIV infection when accompanied by evidence of impaired immune function (see section 4.3).
Okužba s HIV STAMARIL se ne sme uporabljati pri osebah s simptomatsko okužbo HIV ali z asimptomatsko okužbo HIV ob prisotnih dokazih o okrnjenem imunskem delovanju (glejte poglavje 4. 3).
However, there are insufficient data at present to determine the immunological parameters that might differentiate persons who could be safely vaccinated and who might mount a protective immune response from those in whom vaccination could be both hazardous and ineffective.
Zaenkrat ni na razpolago dovolj podatkov za določitev imunskih parametrov, s katerimi bi lahko razlikovali osebe, pri katerih je cepljenje varno in bi lahko vzpostavile zaščitni imunski odgovor, od oseb, pri katerih bi bilo cepljenje lahko nevarno in neučinkovito.
Therefore, if an asymptomatic HIV-infected person cannot avoid travel to an endemic area available official guidance should be taken into account when considering the potential risks and benefits of vaccination.
Kadar se torej asimptomatska oseba z okužbo HIV ne more izogniti potovanju na endemično področje, je treba pri tehtanju pričakovanega tveganja in koristi cepljenja upoštevati razpoložljive uradne smernice.
Children born to HIV positive mothers Children aged at least 6 months (see sections 4.2 and 4.3 and below) may be vaccinated if it is confirmed that they are not infected with HIV.
Otroci HIV- pozitivnih mater Otroke nad 6 mesecev starosti (glejte poglavji 4. 2, 4. 3 in spodaj) se lahko cepi, če je potrjeno, da niso okuženi s HIV.
HIV infected children aged at least 6 months who are potentially in need of protection against yellow fever should be referred to a specialist paediatric team for advice on whether or not to vaccinate.
Otroke nad 6 mesecev starosti, ki so okuženi s HIV in bi potencialno potrebovali zaščito pred rumeno mrzlico, je treba napotiti v specialistični pediatrični dispanzer zaradi posveta glede odločitve o cepljenju ali opustitvi cepljenja.
Age Children aged 6 to 9 months STAMARIL must not be administered to children before the age of 6 months (see section 4.3).
Starost Otroci od 6 do 9 mesecev starosti STAMARIL se ne sme uporabljati pri otrocih pred dopolnjeno starostjo 6 mesecev (glejte poglavje 4. 3).
Children aged from 6 months up to 9 months should only be vaccinated under special circumstances (e.g. during major outbreaks) and on the basis of current official advice.
Otroke v starosti od 6 do 9 mesecev se lahko cepi samo v posebnih okoliščinah (npr. med večjimi epidemijami) in na podlagi veljavnih uradnih priporočil.
Persons aged 60 years and older Some serious and potentially fatal adverse reactions (including systemic and neurological reactions persisting more than 48 hours, YEL-AVD and YEL-AND) appear to occur at higher frequencies after the age of 60 years.
Osebe, stare 60 let in več Zdi se, da se po starosti 60 let nekatere hude in potencialno smrtne neželene reakcije pojavljajo pogostje (vključno s sistemskimi in nevrološkimi reakcijami, ki trajajo dlje kot 48 ur, YEL- AVD in YEL- AND).
Therefore, the vaccine should only be given to those who have a considerable risk of acquiring yellow fever (see above and section 4.8).
Zato je treba cepiti samo osebe s velikim tveganjem za okužbo z rumeno mrzlico (glejte zgoraj in poglavje 4. 8).
16 Because intramuscular injection can cause injection site haematoma, STAMARIL should not be given by the intramuscular route to persons with any bleeding disorder, such as haemophilia or thrombocytopenia, or to persons on anticoagulant therapy.
17 Intramuskularna injekcija lahko povzroči hematom na vbodnem mestu, zato se cepiva STAMARIL ne sme injicirati intramuskularno osebam z motnjami strjevanja krvi, naprimer s hemofilijo ali trombocitopenijo, ali osebam na antikoagulantni terapiji.
The subcutaneous route of administration should be used instead.
Namesto tega je treba dati injekcijo v podkožje.
Patients with rare hereditary problems of fructose intolerance should not take this vaccine.
Pacienti z redkimi dednimi težavami fruktozne intolerance ne smejo prejeti tega cepiva.
STAMARIL must not be mixed with any other vaccine or medicinal product in the same syringe.
Cepiva STAMARIL se ne sme mešati z nobenim drugim cepivom ali zdravilom v isti brizgalki.
If there is a need to administer another injectable vaccine(s) at the same time as STAMARIL each vaccine should be injected into a separate site (and preferably a separate limb).
Če je treba hkrati s cepivom STAMARIL uporabiti še kakšno drugo cepivo za injiciranje, naj se vsako cepivo injicira na svoje vbodno mesto (po možnosti na različna uda).
STAMARIL may be administered at the same time as measles vaccine if this is in accordance with official recommendations.
STAMARIL se lahko uporabi hkrati s cepivom proti ošpicam, če je to v skladu z uradnimi priporočili.
STAMARIL may be administered at the same time as vaccines containing typhoid Vi capsular polysaccharide and/or inactivated hepatitis A virus.
STAMARIL se lahko uporabi hkrati s cepivi, ki vsebujejo tifoidni Vi kapsularni polisaharid in/ ali inaktiviran virus hepatitisa A.
STAMARIL must not be administered to persons who are receiving immunosuppressant therapy (e.g., cytotoxic agents, systemic steroids, greater than standard dose of topical or inhaled steroids or other agents).
Cepiva STAMARIL se ne sme uporabljati pri osebah, ki prejemajo imunosupresivno terapijo (npr. citotoksična sredstva, sistemske steroide, večji odmerki topičnih ali inhalacijskih steroidov kot običajno ali druga sredstva).
Pregnancy No animal reproduction studies have been conducted with STAMARIL and the potential risk for humans is unknown.
Nosečnost Študije na živalih ne zadostujejo za oceno vpliva na nosečnost, razvoj zarodka in postnatalni razvoj.
Data on a limited number of exposed pregnancies indicate no adverse effects of STAMARIL on pregnancy or the health of the fetus/newborn child.
Podatki, zbrani pri omejenem številu nosečnic, ki so bile izpostavljene zdravilu, ne kažejo na možnost škodljivih vplivov cepiva STAMARIL na nosečnost ali zdravje zarodka/ novorojenca.
Nevertheless, STAMARIL should be given to pregnant women only when clearly needed and only after careful consideration of the potential risks and benefits.
Kljub temu se sme STAMARIL uporabiti pri nosečnicah samo v primerih, ko je to nujno potrebno, in ob skrbnem upoštevanju potencialnih tveganj in koristi.
Lactation It is not known if the live attenuated yellow fever virus is excreted in animal or human breast milk.
Dojenje Ni znano, ali se oslabljen živ virus rumene mrzlice izloča v živalsko ali človeško mleko.
Although there have been no reports of transmission of vaccine viruses from breastfeeding mothers to infants STAMARIL should not be given to nursing mothers unless this cannot be avoided.
Čeprav ni poročil o prenosu virusov cepiva iz doječih mater na dojenčke, se cepiva STAMARIL ne sme uporabiti pri doječih materah, razen v neizogibnih primerih.
No studies on the effects on the ability to drive or use machine have been performed.
Študij o vplivu na sposobnost vožnje in upravljanja s stroji niso izvedli.
Data from clinical studies Across clinical studies, the most common adverse reactions occurring after vaccine administration were local reactions, reported in approximately 16% of subjects.
Podatki iz kliničnih raziskav V kliničnih raziskavah so bile najpogostejše neželene reakcije po uporabi cepiva lokalne reakcije, ki so jih zabeležili pri približno 16% preiskovancev.
The following adverse events are from one clinical study in which 106 healthy adult subjects received STAMARIL..
Naslednji neželeni učinki izhajajo iz klinične raziskave, v kateri je 106 zdravih odraslih preiskovancev prejelo STAMARIL.
The adverse events are ranked under headings of frequency, using the following convention:
Neželeni učinki so razvrščeni po pogostnosti v skladu s naslednjim dogovorom:
Very common: ≥ 10% Common:: ≥ 1% and ≤ 10% Uncommon:: ≥ 0.1% and ≤ 1%
(> 0. 1% in < 1 /%)
Headache
Bolezni živčevja Zelo pogosti: glavobol
17 Gastro-intestinal system disorders Common:
18 Presnovne in prehranske motnje Pogosti:
Nausea, Diarrhoea, Vomiting Abdominal pain
slabost, driska, bruhanje bolečine v trebuhu
Musculo-skeletal and connective tissue disorders Common:
Bolezni mišično- skeletnega sistema in vezivnega tkiva Pogosti:
Myalgia Arthralgia
bolečine v mišicah bolečine v sklepih
General disorders and administration site conditions Very common:
Splošne težave
Local reactions (including pain, redness, haematoma, induration, swelling) Common:
Zelo pogosti: lokalne reakcije (vključujejo bolečino, rdečino, hematom, zatrdlino, oteklino) Pogosti:
Pyrexia, Asthenia
mrzlica, splošna oslabelost
Data from post-marketing experience The following additional adverse events have been reported during post marketing experience with STAMARIL.
Podatki iz post- marketinških izkušenj O naslednjih dodatnih neželenih učinkih so poročali v okviru post- marketinških izkušenj s cepivom STAMARIL.
They are based on spontaneous reporting therefore the frequencies are unknown.
Podatki temeljijo na spontanem poročanju, zato pogostnosti niso znane.
Immune system disorders Anaphylaxis, angioedema.
Bolezni imunskega sistema Anafilaksa, angioedem
Nervous system disorders Cases of neurotropic disease (known as YEL-AND), some of which have had a fatal outcome, have been reported following yellow fever vaccination (see section 4.4).
Bolezni živčevja Obstajajo poročila o primerih nevrotropne bolezni po cepljenju proti rumeni mrzlici (imenovane YEL - AND), nekateri so se končali s smrtnim izidom (glejte poglavje 4. 4).
YEL-AND may manifest as high fever with headache that may progress to include one or more of confusion, lethargy, encephalitis, encephalopathy and meningitis (see section 4.4).
YEL- AND se kaže kot visoka vročina z glavobolom, ki lahko napreduje in vključuje enega ali več od naslednjih stanj: zmedenost, zaspanost, encefalitis, encefalopatija in meningitis (glejte poglavje 4. 4).
Other neurological signs and symptoms have been reported and include convulsion, Guillain-Barré syndrome and focal neurological deficits.
Poročajo tudi o drugih nevroloških znakih in simptomih, ki vključujejo sindrom Guillain- Barré in žariščne nevrološke izpade.
Skin and subcutaneous tissue disorders Rash, Urticaria
Bolezni kože in podkožja Izpuščaj, utrikarija
General disorders and administration site conditions Cases of viscerotropic disease (known as YEL-AVD and formerly described as “Febrile Multiple Organ-System Failure”) have been reported following yellow fever vaccination some of which have been fatal (see section 4.4).
Splošne težave in spremembe na mestu aplikacije Obstajajo poročila o primerih viscerotropne bolezni po cepljenju proti rumeni mrzlici (imenovane YEL- AVD, star izraz je "febrilna odpoved multiplih organskih sistemov"), nekateri so se končali s smrtnim izidom (glejte poglavje 4. 4).
YEL-AVD may manifest as fever, fatigue, myalgia, headache and hypotension progressing to one or more of metabolic acidosis, muscle and liver cytolysis, lymphocytopenia and thrombocytopenia, renal and respiratory failure.
YEL- AVD se kaže kot vročina, utrujenost, bolečine v mišicah, glavobol in hipotenzija, ki napreduje v eno ali več od naslednjih stanj: metabolna acidoza, mišična in jetrna citoliza, limfocitopenija in trombocitopenija, ledvična in dihalna odpoved.
Additional information on special population Congenital or acquired immunodeficiency has been identified as a risk factor for neurotropic disease (See sections 4.3 and 4.4).
Dodatne informacije o posebnih skupinah pacientov Prirojena ali pridobljena imunska pomanjkljivost je dejavnik tveganja za nevrotropno bolezen (glejte poglavji 4. 3 in 4. 4).
Age of more than 60 years (see section 4.4) has been identified as a risk factor for YEL-AVD and YEL-AND.
Starost več kot 60 let (glejte poglavje 4. 4) je dejavnik tveganja za YEL- AVD in YEL- AND.
A medical history of thymic disease (see sections 4.3 and 4.4) has been identified as a risk factor for YEL-AVD.
Anamneza bolezni timusa (glejte poglavji 4. 3 in 4. 4) je dejavnik tveganja za YEL- AVD.
18 5.1 Pharmacodynamic properties
Farmakodinamične lastnosti
Pharmacotherapeutic group:
19 Farmakoterapevtska skupina:
Yellow Fever Vaccine (Live) ATC code:
Cepivo proti rumeni mrzlici, živo ATC koda:
STAMARIL is a live attenuated yellow fever virus vaccine.
STAMARIL je cepivo z živim oslabljenim virusom rumene mrzlice.
As with other live attenuated viral vaccines, there is a sub-clinical infection in healthy recipients that results in the production of specific B and T cells and the appearance of specific circulating antibody.
Kot pri drugih živih oslabljenih virusnih cepivih nastane pri zdravih prejemnikih subklinična okužba, ki povzroči produkcijo specifičnih B in T celic in pojav specifičnih krožečih protiteles.
Protective immunity appears from about 10 days after injection.
Zaščitna imunost se pojavi po približno 10 dneh od injekcije.
Although International Health Regulations require re-vaccination at intervals of 10 years in order to retain a valid certificate, some degree of immunity likely persists for more than 10 years.
Čeprav Mednarodna zdravstvena pravila za ohranitev veljavnosti potrdila zahtevajo revakcinacijo v časovnih presledkih po 10 let, določena stopnja imunosti verjetno ostane tudi po preteku 10 let.
No pharmacokinetic studies have been performed.
Farmakokinetične raziskave niso bile opravljene.
Pre-clinical data reveal no special hazard for humans.
Predklinični podatki niso pokazali nobenega posebnega tveganja za človeka.
Lactose Sorbitol E420 L-histidine hydrochloride L-alanine Sodium chloride Potassium chloride Disodium phosphate Monopotassium phosphate Calcium chloride Magnesium sulphate
Prašek: laktoza monohidrat sorbitol E4 20 L- histidinijev klorid monohidrat L- alanin natrijev klorid kalijev klorid natrijev hidrogenfosfat dihidrat kalijev dihidrogenfosfat kalcijev klorid dihidrat magnezijev sulfat heptahidrat
Sodium chloride Water for injections.
Vehikel: natrijev klorid voda za injekcije
This vaccine must not be mixed with other medicinal products.
6. 2 Inkompatibilnosti
After reconstitution, the medicinal product must be used immediately.
Po rekonstituciji je treba zdravilo takoj uporabiti.
Keep the vial in the outer carton in order to protect from light.
Shranjujte vialo v zunanjem ovoju zaradi zaščite pred svetlobo.
19 For storage conditions of the reconstituted medicinal product, see section 6.3
Za pogoje shranjevanja rekonstituiranega zdravila glejte poglavje 6. 3.
Powder in vial (type I glass), with stopper (chlorobutyl) and aluminium flip-off cap + 0.5 ml of solvent in pre-filled syringe (type I glass), with a plunger-stopper (chlorobromobutyl), attached needle and needle-shield (natural rubber or polyisoprene) or tip-cap (chlorobromobutyl) – pack size of 1, 10 or 20.
Prašek v viali (steklo tipa I), z zamaškom (klorobutil) in aluminijasto zaporko + 0, 5 ml topila v napolnjeni injekcijski brizgi (steklo tipa I), z zamaškom na batu (klorobromobutil), pritrjeno iglo in igelnim ščitnikom (naravna guma ali poli- izopren) ali pokrovom za konico (klorobromobutil) - velikost zavoja po 1, 10 ali 20.
The following presentations may not be registered depending on the country.
Naslednje vrste ovojnine morda ne bodo registrirane, odvisno od države.
Their implementation will be reviewed nationally.
Njihova uvedba bo določena nacionalno.
Powder in vial (type I glass), with stopper (chlorobutyl) and aluminium flip-off cap + 0.5 ml of solvent in pre-filled syringe (type I glass), with a plunger-stopper (chlorobromobutyl), without attached needle and tip-cap (chlorobromobutyl) – pack size of 1, 10 or 20.
Prašek v viali (steklo tipa I), z zamaškom (klorobutil) in aluminijasto zaporko + 0, 5 ml topila v napolnjeni injekcijski brizgi (steklo tipa I), z zamaškom na batu (klorobromobutil), brez pritrjene igle in pokrova za konico (klorobromobutil) - velikost zavoja po 1, 10 ali 20.